Vsf1.01

Clinical trials are investigating Vsf1.01 in people with hearing loss who are receiving cochlear implants. The main goal is to check safety and record side effects after intracochlear injection during surgery. This research is in an early phase and includes a small group of patients.

Table of Contents

Trial overview

The available clinical trial is titled Intracochlear application of Vsf1.01 for the reduction of cochlear implant surgery related trauma, also called the ESCRT study.[1]

This study is testing Vsf1.01 as an added treatment during cochlear implant surgery, with the medicine given by intracochlear injection, which means an injection placed directly into the cochlea.[1]

The trial is authorised and planned as an interventional study, so researchers actively give the study treatment and then observe what happens.[1]

Who is being studied

The trial is for patients with hearing loss who are receiving cochlear implantation.[1]

The source data do not list more detailed inclusion or exclusion rules, so the exact participation criteria are not available here.[1]

The planned enrollment is 11 people, which means this is a very small early study.[1]

Study design and phase

This is a Phase 1/2 trial, which is an early stage of clinical research.[1]

Early phase studies usually focus on safety first and may also give early information that can guide future research.[1]

The study is described as interventional, meaning the researchers are testing a treatment rather than only observing patients.[1]

What the trial measures

The main goal of the study is to assess safety of Vsf1.01 when used during cochlear implantation.[1]

The primary endpoint is the number and severity of adverse events and serious adverse events, which are medical problems that happen during the study and are carefully recorded.[1]

These safety results are meant to create a safety profile for Vsf1.01 in this surgical setting.[1]

What this study may mean for patients

For patients, this trial is mainly about learning whether Vsf1.01 can be used safely during cochlear implant surgery.[1]

Because the study is small and early, it is not designed to prove long-term benefit, but to collect first safety data in people with hearing loss who need cochlear implants.[1]

The study focus on surgery related trauma shows that researchers are looking at whether the treatment may help reduce injury linked to the implant procedure.[1]

Trial IDPhaseCondition studiedStatusEnrollment
2024-512498-29-00Phase 1/2Hearing loss; cochlear implant surgery related traumaAuthorised11

Ongoing Clinical Trials on Vsf1.01

  • Study on VSF1.01 for Reducing Surgery Trauma in Hearing Loss Patients Receiving Cochlear Implants

    Recruiting

    2 1 1
    Investigated drugs:
    Germany

Glossary

  • Cochlear implant: A device placed in the inner ear to help some people with severe hearing loss hear sounds better.
  • Cochlea: A spiral-shaped part of the inner ear that helps change sound into signals the brain can understand.
  • Intracochlear injection: An injection placed directly into the cochlea.
  • Interventional study: A clinical trial where researchers give a treatment and then watch what happens.
  • Phase 1/2: An early stage of clinical research. Phase 1/2 studies usually focus on safety and may also look for early signs that the treatment could help.
  • Safety profile: A summary of how safe a treatment appears to be based on the side effects and other medical events seen in the trial.
  • Adverse event: A medical problem that happens during a study, whether or not it is caused by the treatment.
  • Serious adverse event: A more serious medical problem during a study, such as one that is life-threatening, needs hospital care, or causes major harm.
  • Enrollment: The number of people planned to join or actually included in a clinical trial.
  • Authorised: The trial has been approved to run.

References

  1. https://clinicaltrials.gov/study/2024-512498-29-00